Nishanthan Rajakumaraswamy

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Acute Myeloid Leukemia

Multiple Myeloma

Tyrosine Kinase

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Clinical and translational science

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Anthony W Tolcher, Joshua D Brody, Nishanthan Rajakumaraswamy, Michelle R Kuhne, Torsten Trowe, Anees M Dauki, Shantheri Pai, Ling Han, Kai-Wen Lin, Michael Petrarca, Shivaani Kummar
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Anthony W Tolcher, Joshua D Brody, Nishanthan Rajakumaraswamy, Michelle R Kuhne, Torsten Trowe, Anees M Dauki, Shantheri Pai, Ling Han, Kai-Wen Lin, Michael Petrarca, Shivaani Kummar
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Anthony W Tolcher, Joshua D Brody, Nishanthan Rajakumaraswamy, Michelle R Kuhne, Torsten Trowe, Anees M Dauki, Shantheri Pai, Ling Han, Kai-Wen Lin, Michael Petrarca, Shivaani Kummar
Phase I Study of GS-3583, a FLT3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Anthony W Tolcher, Joshua D Brody, Nishanthan Rajakumaraswamy, Michelle R Kuhne, Torsten Trowe, Anees M Dauki, Shantheri Pai, Ling Han, Kai-Wen Lin, Michael Petrarca, Shivaani Kummar
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Anees M Dauki, Nishanthan Rajakumaraswamy, Torsten Trowe, Winnie Weng, Kai-Wen Lin, Emon Elboudwarej, Ann Ran-Ran Qin, Christian Schwabe, Michelle R Kuhne, Ahmed A Othman
Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participants. Clinical and translational science 17 (8) (2024)
Anees M Dauki, Nishanthan Rajakumaraswamy, Torsten Trowe, Winnie Weng, Kai-Wen Lin, Emon Elboudwarej, Ann Ran-Ran Qin, Christian Schwabe, Michelle R Kuhne, Ahmed A Othman
Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participants. Clinical and translational science 17 (8) (2024)
Barry A Paul, Michaela Liedtke, Jack Khouri, Robert M Rifkin, Mitul D Gandhi, Andrew Kin, Moshe Y Levy, Rebecca W Silbermann, Francesca Cottini, Douglas W Sborov, Irwindeep Sandhu, Lyssa Villarreal, Michael Murphy, Lin Gu, Ann Chen, Nishanthan Rajakumaraswamy, Saad Z Usmani
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma. Future oncology (London, England) (2023)
Judith Trotman, Martin J S Dyer, Harriet Sarah Walter, Alexey V Danilov, Loic Ysebaert, Daniel James Hodson, Christopher Fegan, Simon A Rule, John Radford, Guillaume Cartron, Krimo Bouabdallah, Andrew John Davies, Stephen Spurgeon, Nishanthan Rajakumaraswamy, Biao Li, Rita Humeniuk, Xi Huang, Pankaj Bhargava, Juliane M Jürgensmeier, Gilles Andre Salles
Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. Leukemia 35 (7) (2020)